MavriX Bio
PrivateLast Round
Corporate Funding
Feb 14, 2025
Company Overview
MavriX Bio is a biotechnology company developing gene replacement therapies for the treatment of Angelman syndrome.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
MavriX Bio Comparables
Compare MavriX Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Encoded Therapeutics | 88% | |
| Oak Hill Bio | 83% | |
| Couragene | 78% | |
MavriX Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Corporate Funding | Feb 14, 2025 |
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 14, 2025
Led by Foundation for Angelman Syndrome Therapeutics and AS²Bio Inc.
MavriX Bio Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about MavriX Bio's valuation, stock price, and market status.